Genuity Science
Genuity Science is a privately-held, Dublin-based clinico-omics data company that builds disease-specific, whole-genome sequencing cohorts enriched with deep phenotypic data and licenses restricted access to pharmaceutical and biotechnology partners for target discovery, biomarker identification, and clinical trial design in CNS, cardiometabolic, and inflammatory diseases.
- Company typePrivate
- Founded2013
- HeadquartersBoston, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Genuity Science does
Genuity Science (Ireland) Limited is a privately-funded life sciences company, formerly known as Genomics Medicine Ireland and WuXi NextCODE, wholly owned by US-based biotech HiberCell Inc. The company operates a CAP-accredited genomics laboratory in Cherrywood, Co. Dublin and maintains a registered office in Dun Laoghaire, with operational footprints in the US (Boston) and the UK. It builds and curates disease-specific clinico-omic cohorts — combining whole-genome sequencing, multi-omic data, and longitudinal clinical/phenotypic information — across eight conditions: Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Inflammatory Bowel Disease, Lupus, Heart Failure, Liver Disease, and Diabetic and Non-diabetic Nephropathy. Cohort construction draws on an established network of hospital, academic, and primary-care partners in Ireland, the UK, and the US (including Emory, Vanderbilt, Yale, Cambridge, UMass, USC, and Vanderbilt University Medical Center). All data handling is GDPR-compliant and operates under Irish Data Protection and Health Research regulations, with ISO-certified EU cloud storage.
The company monetizes through multi-year, bespoke commercial research agreements in which pharmaceutical and biotechnology partners receive restricted read-only access to select de-identified datasets and associated analytics. Application areas are organized around four service lines: Target Discovery (genetic-evidence-driven target identification), Portfolio Optimization (candidate target/biomarker validation), Clinical Trials (sub-population identification for study design and enrollment), and Biomarker Discovery (higher-resolution disease stratification). Underlying capabilities include Custom Cohorts, Next Generation Sequencing, and Data Analysis services led by published scientists, supported by what the company describes as the industry's only data analysis platform purpose-built for population-scale genomics and integrating deep learning methods.
The go-to-market is enterprise field sales: named commercial partners include AbbVie (since 2017, the longest-tenured relationship), Vesalius Therapeutics (2022, Parkinson's focus), Ionis Pharmaceuticals (2024, antisense drug development), and Alumis Inc (2026, multi-disease). Cumulative disclosed equity funding totals roughly $455M across rounds in 2013, 2017, and 2018, with the most recent $200M Series 3 led by the Ireland Strategic Investment Fund alongside Sequoia Capital, Temasek, and YF Capital. The company employs 101–250 people and has no public revenue disclosure. Pricing is not publicly disclosed; contracts are individually negotiated.
Genuity Science firmographics
Firmographics- Name
- Genuity Science
- Legal name
- Genuity Science (Ireland) Limited
- Website
- https://genuitysci.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Genuity Science is a privately-held, Dublin-based clinico-omics data company that builds disease-specific, whole-genome sequencing cohorts enriched with deep phenotypic data and licenses restricted access to pharmaceutical and biotechnology partners for target discovery, biomarker identification, and clinical trial design in CNS, cardiometabolic, and inflammatory diseases.
- Ownership category
- akta.pro rank
Genuity Science industry classification
Industry- Product category
- Population Genomics Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Population Genomics & Preventive Precision Health Programs (HLAAANAL), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Genuity Science is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Genuity Science business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Commercial Research Partnerships: Genuity Science provides pharmaceutical and biotechnology companies with restricted read-only access to select de-identified datasets for commercial research purposes. Partners pay for access to data and analysis services through multi-year research agreements.
- Genomics Services: End-to-end genomics services including study design, cohort sourcing, sample preparation, sequencing, and advanced analytics applied to genotypic and phenotypic data for commercial and academic research partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Genuity Science product offering
Product offeringCore offering
Genuity Science provides population-scale genomics and clinico-omic data products and services to pharmaceutical and biotechnology companies for drug discovery. The company combines retrospective and prospective disease-specific datasets with whole genome sequencing, deep phenotypic data, and multi-omic analysis powered by deep learning methods to support target discovery, biomarker identification, clinical trial design, and portfolio optimization across CNS, cardiometabolic, and inflammatory disease areas.
Product overview
Genuity Science is a life sciences company offering a portfolio of genomics services and disease-specific data products to accelerate drug discovery in CNS, cardiometabolic, and inflammatory diseases. The core offerings include Target Discovery, Portfolio Optimization, Clinical Trials support, and Biomarker Discovery services, all powered by Population Genomics and Population Multi-Omics datasets. Supporting services include Custom Cohorts, Next Generation Sequencing (from their CAP-accredited genomics laboratory), and Data Analysis services led by published scientists. The company provides disease-specific datasets across eight conditions: Alzheimer's, Diabetic and Non-diabetic Nephropathy, Heart Failure, Inflammatory Bowel Disease, Liver Disease, Lupus, Multiple Sclerosis, and Parkinson's. The company is owned by HiberCell Inc. and was previously known as Genomics Medicine Ireland and WuXi NextCODE.
Differentiator
Problem solved
Functional benefit
Products and services
- Population Genomics Curated, disease-specific, longitudinal deep phenotyped genomic cohorts in CNS, cardiometabolic, and inflammatory disease areas, powered for statistical significance with whole genome data, sold to pharmaceutical and biotechnology companies for research use.
- Population Multi-Omics Focused multi-omic sub-cohorts built from each population genomic cohort, enabling clients to combine genetic evidence with biological function to establish causality and effect for therapeutic discovery.
- Custom Cohorts Custom disease-specific cohort building service providing statistically powered cohorts with whole genome data enriched with deep phenotypic data for longitudinal insight, tailored to client research requirements.
- Next Generation Sequencing Whole genome sequencing service delivered through a CAP-accredited genomics laboratory, providing high-quality, scalable genomic services with world-class expertise and personalized service for research partners.
- Data Analysis Advanced analytics services for genomic and phenotypic data led by published scientists, covering predictive analytics, process automation, and disease-progression modeling on population-scale datasets.
- Target Discovery Service that identifies novel therapeutic targets with strong genetic evidence to support drug discovery programs in CNS, cardiometabolic, and inflammatory diseases, using the company's clinico-omic datasets.
- Portfolio Optimization Service that validates candidate drug targets and biomarkers to help pharmaceutical clients focus R&D investment, leveraging Genuity Science's disease-specific clinico-omic datasets.
- Clinical Trials Support Service that supports clinical trial design by identifying relevant patient sub-populations and informing enrollment criteria using the company's genomic and phenotypic datasets.
- Biomarker Discovery Service that discovers novel biomarkers enabling higher resolution disease stratification for improved patient targeting and therapeutic outcomes in CNS, cardiometabolic, and inflammatory diseases.
Quantifiable outcome
- Multi-year partnerships with major pharmaceutical companies (AbbVie since 2017, Vesalius 2022, Ionis 2024) demonstrate commercial validation of platform.
Companies that use Genuity Science
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Genuity Science technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature7 records
Genuity Science partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core, supporting and flagship.
- Alumis InccoreGenuity Science began a project with Alumis Inc in 2026. The goal is to bring together comprehensive datasets including multiple disease areas to enable better understanding of drivers of disease and therapeutic response, with the aim of optimising therapeutic outcomes for patients.
- Ionis PharmaceuticalscoreGenuity Science began a multi-year agreement in 2024 with Ionis Pharmaceuticals. The goal is to bring together a comprehensive database to enable better understanding of disease mechanisms which, combined with Ionis' proprietary antisense technology, has the potential to significantly expedite drug development through more direct translation of targets into therapies.
- Vesalius TherapeuticscoreGenuity Science began a multi-year agreement in 2022 with Vesalius Therapeutics. The goal is to bring together a comprehensive database to enable evaluation of variability among patients with Parkinson's disease to better understand disease severity and symptoms. Designed to facilitate identification of more refined patient subpopulations for advancement of specific therapeutic agents in specific patient subpopulations.
- AbbViecoreGenuity Science (then Genomics Medicine Ireland and WuXi NextCODE) commenced a partnership with AbbVie in 2017. As part of the collaboration, Genuity Science conducts population genomics research aimed at advancing the discovery of novel therapeutic approaches to major chronic diseases. This is the company's longest-standing commercial partnership.
- Emory UniversitysupportingAcademic research partnership for population genomics research collaboration.
- Nashville BiosciencessupportingAcademic research partnership for population genomics research collaboration.
- University of CambridgesupportingAcademic research partnership for population genomics research collaboration based in the UK.
- University of Massachusetts Medical CentersupportingAcademic research partnership for population genomics research collaboration.
- University of Southern CaliforniasupportingAcademic research partnership for population genomics research collaboration.
- Vanderbilt University Medical CentersupportingAcademic research partnership for population genomics research collaboration.
- Yale University Medical CentersupportingAcademic research partnership for population genomics research collaboration.
- HiberCell Inc.flagshipGenuity Science (Ireland) Limited is owned by HiberCell Inc., a US-based biotech company. HiberCell is the parent company of Genuity Science.
- Hospital, Academic and Clinical Research Centers (Ireland)supportingNetwork of Irish healthcare and research institutions providing clinical sites for population genomics studies and cohort recruitment.
- Primary Care Centers (UK)supportingUK-based primary care centres participating in population genomics research collaborations.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Genuity Science competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine: Roche-owned molecular genomics profiling company serving oncology drug development; comparable in pharma partnership model and genomic data licensing, though focused on oncology rather than CNS/cardiometabolic/inflammatory.
- UK Biobank: Large-scale public population genomics and health database with 500,000+ participants; serves as both a substitute (free academic access) and complement (validation cohort) to commercial population genomics providers.
- Verily Life Sciences: Alphabet-subsidiary precision health platform operating population-scale studies (e.g., Project Baseline) combining genomics, multi-omics, and clinical data — comparable in scale and pharma partnership model.
Emerging players
- Tempus Labs: AI-enabled precision medicine company with multi-modal (DNA, RNA, imaging, clinical) data library licensed to pharma; comparable data-licensing business model with broader therapeutic coverage including oncology and neuropsychiatry.
Direct peers
- deCODE Genetics: Amgen-owned population genomics platform focused on disease gene discovery using large-scale WGS and deep phenotypic data from the Icelandic population — directly comparable business model and disease-cohort focus.
- Human Longevity Inc. Combines whole-genome sequencing, multi-omic profiling, and AI-driven analysis to build a comprehensive health database — comparable technology stack and target customer base in pharma and preventive health.
- Helix: Population genomics and clinical genomic sequencing platform partnering with health systems and pharma; offers similar CAP-accredited sequencing and population-scale data assets for research and clinical applications.
- 23andMe Therapeutics: Consumer-genomics platform with a therapeutics arm that licenses population genomic data and targets to pharma — comparable in monetizing population-scale genetic data for drug discovery.
- Regeneron Genetics Center: Operates one of the world's largest human genetics databases linked to electronic health records; partners with pharma for target discovery and validation — directly comparable data-platform-as-a-service model.
Others
- Bristol Myers Squibb (Celgene) Genetic Analysis Platform: Large pharma with internal population genomics programs that compete for pharma R&D budget allocation; relevant as both potential customer and competitor building similar in-house capabilities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genuity Science social profiles
Digital presenceGenuity Science compliance and trust
Trust signalCompliance2 records
Genuity Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genuity Science leadership team
Management profileNumber of profiles
Profiles5 records
Genuity Science funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genuity Science M&A and investment
M&A and investmentM&A1 record
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genuity Science
What does Genuity Science do?
Genuity Science provides population-scale genomics and clinico-omic data products and services to pharmaceutical and biotechnology companies for drug discovery. The company combines retrospective and prospective disease-specific datasets with whole genome sequencing, deep phenotypic data, and multi-omic analysis powered by deep learning methods to support target discovery, biomarker identification, clinical trial design, and portfolio optimization across CNS, cardiometabolic, and inflammatory disease areas.
Is Genuity Science a public or private company?
Genuity Science is a private company. It is classified as corporate owned and is currently operating.
When was Genuity Science founded?
Genuity Science was founded in 2013. It employs 101 to 250 people.
Where is Genuity Science based?
Genuity Science is headquartered in Boston, United States, in the North America region.
How does Genuity Science make money?
Two revenue lines are on record. Commercial Research Partnerships are the primary driver. The others are genomics Services.
Who are Genuity Science's main competitors?
Broad incumbents on record are Foundation Medicine, UK Biobank and Verily Life Sciences. Tempus Labs is listed as an emerging player. Direct peers are deCODE Genetics, Human Longevity Inc., Helix, 23andMe Therapeutics and Regeneron Genetics Center. Bristol Myers Squibb (Celgene) Genetic Analysis Platform is listed as an others.
Does Genuity Science have an API?
No public API is recorded for Genuity Science.
What industry is Genuity Science in?
Genuity Science's product category is Population Genomics Services. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 541714 and its SIC code is 8071.